During tumor progression, the EMT process significantly enhances tumor cell resistance to chemotherapeutic drugs by promoting the expression of EMT-related transcription factors such as E-box binding homeobox 1 (ZEB1), E-box binding homeobox 2 (ZEB2), and TWIST1 (75, 76). Here, ZEB2 is linked to neoplasm.